查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585793

脑生物标记市场：按产品、适应症、最终用户和应用 - 全球预测 2025-2030

Brain Biomarkers Market by Product (Biomarker Analyzers, Biomarker Test Kits), Indication (Alzheimer's Disease, Huntington's Disease, MND & ALS), End-Users, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，脑生物标记市场估值为89.4亿美元，预计到2024年将达到105.4亿美元，复合年增长率为17.90%，到2030年将达到283.3亿美元。

大脑生物标记是大脑生物过程的可测量指标，通常用于评估神经系统状况。它对于阿兹海默症、帕金森氏症和各种精神疾病的诊断和监测至关重要。这些生物标记的范围从遗传和蛋白质组到成像和生理讯号。对大脑生物标记的需求在于它们能够促进早期诊断、追踪疾病进展、制定个人化治疗计划以及显着改善患者治疗结果和医疗保健效率。

主要市场统计
基准年[2023] 89.4亿美元
预测年份 [2024] 105.4亿美元
预测年份 [2030] 283.3亿美元
复合年增长率（%） 17.90%

大脑生物标记的应用涵盖诊断、药物开发和治疗监测。它被医院、研究机构和临床实验室僱用，为神经科、精神病学家和其他医疗保健专业人员提供服务。神经系统疾病的日益普及、个人化医疗需求的不断增长以及生物标记技术的进步推动了大脑生物标记市场的发展。新的商机包括整合人工智慧和机器学习以增强生物标记的发现和分析，以及探索心理健康领域的生物标记。

关键的成长要素包括神经影像和基因组学的技术进步、对大脑健康意识的提高以及对精准医疗的投资增加。然而，生物标誌物发现和检验的高成本、监管的复杂性以及纵向资料的有限可用性等挑战构成了主要障碍。此外，有关基因测试和资料隐私的道德考虑可能会影响市场动态。

需要开拓创新领域，例如检测复杂生物标记的多组体学、开发非侵入性生物标记检测方法以及生物技术公司和研究机构之间的合作以加速研发。更加重视整合患者特定资料以完善预测模型的个人化医疗方法预计将扩大市场。

总之，在技术进步和医疗保健需求的推动下，大脑生物标记市场已准备好成长。应对挑战需要对研究进行策略性投资、跨学科合作、强大的监管环境来驾驭道德和技术环境，以及创新和扩大市场的新创新。

市场动态：揭示快速发展的大脑生物标记市场的关键市场洞察

供需的动态交互作用正在改变大脑生物标记市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 研发投资旨在提高对神经系统疾病的了解并治疗不断增长的老年人群中的脑部疾病
    • 需要侵入性脑部测试、有效的药物开发、快速诊断和新的治疗选择
    • 检测和解释以支持临床决策和患者干预
  • 市场限制因素
    • 缺乏消费者意识
  • 市场机会
    • 支持基于生物标记的药物开发和转化研究的生物标记资料管理平台的演变
    • 将可检测参数纳入大脑生物标记以改善临床决策
  • 市场挑战
    • 生物异质性进一步加剧了发炎的复杂性。

波特五力：驾驭脑部生物标记市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解大脑生物标记市场的外部影响

外部宏观环境因素在塑造大脑生物标记市场的动态表现方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解大脑生物标记市场的竞争状况

对大脑生物标记物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵脑生物标记市场供应商的绩效评估

FPNV定位矩阵是评估大脑生物标记市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了大脑生物标记市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对脑生物标记市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 研发投资旨在提高对神经系统疾病的了解并治疗不断增长的患有脑部疾病的老年人口
      • 需要侵入性脑部测试、有效的药物开发、更快的诊断和新的治疗选择
      • 检测和解释以支持临床决策和患者干预
    • 抑制因素
      • 缺乏消费者意识
    • 机会
      • 不断发展的生物标记资料管理平台，支援基于生物标誌物的药物开发和转化研究
      • 将可检测参数纳入大脑生物标记以改善临床决策
    • 任务
      • 生物多样性加剧了发炎的复杂性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章脑生物标记市场：副产品

  • 生物标记分析仪
  • 生物标记检测套组

第七章依适应症分類的脑生物标记市场

  • 阿兹海默症
  • 亨丁顿舞蹈症
  • 肌萎缩侧索硬化症和肌萎缩侧索硬化症
  • 帕金森氏症
  • 中风

第 8 章 脑生物标记市场：依最终用户分类

  • 门诊手术中心
  • 诊断实验室
  • 医院
  • 研究室

第九章脑生物标记市场：依应用分类

  • 诊断
  • 药物发现与开发

第10章美洲脑生物标记市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区脑生物标记市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的脑生物标记市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Advanced Brain Monitoring, Inc
  • Biognosys AG
  • BrainScope Company, Inc.
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Johnson & Johnson
  • Lifesign LLC
  • Magstim EGI
  • Merck KGaA,
  • Natus Medical Inc.
  • NeuroVista Corporation
  • Nexus-DX
  • PhenoSwitch Bioscience
  • Seimens Healthnineers
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43150DF82D01

The Brain Biomarkers Market was valued at USD 8.94 billion in 2023, expected to reach USD 10.54 billion in 2024, and is projected to grow at a CAGR of 17.90%, to USD 28.33 billion by 2030.

Brain biomarkers are measurable indicators of biological processes within the brain, often used for assessing neurological conditions. They are vital for diagnosing and monitoring diseases like Alzheimer's, Parkinson's, and various psychiatric disorders. These biomarkers range from genetic and proteomic to imaging and physiological signals. The necessity of brain biomarkers lies in their ability to facilitate early diagnosis, track disease progression, and tailor personalized treatment plans, significantly improving patient outcomes and healthcare efficiency.

KEY MARKET STATISTICS
Base Year [2023] USD 8.94 billion
Estimated Year [2024] USD 10.54 billion
Forecast Year [2030] USD 28.33 billion
CAGR (%) 17.90%

The application of brain biomarkers spans diagnostics, drug development, and therapeutic monitoring. They are employed in hospitals, research institutes, and clinical labs, serving neurologists, psychiatrists, and other healthcare professionals. The market for brain biomarkers is bolstered by increasing prevalence of neurological disorders, growing demand for personalized medicine, and advances in biomarker technologies. Emerging opportunities include the integration of AI and machine learning to enhance biomarker discovery and analysis, as well as the exploration of biomarkers in the mental health domain.

Key growth factors include technological advancements in neuroimaging and genomics, rising awareness about brain health, and increasing investments in precision medicine. However, challenges such as the high cost of biomarker discovery and validation, regulatory complexities, and limited availability of longitudinal data pose significant hurdles. Moreover, ethical considerations related to genetic testing and data privacy could impact market dynamics.

Innovative areas ripe for exploration include multi-omics approaches to detect composite biomarkers, development of non-invasive biomarker detection methods, and collaborations between biotech firms and research institutions for accelerated R&D. A deeper focus on personalized health approaches, integrating patient-specific data to refine predictive models, holds promise for market expansion.

In conclusion, the brain biomarker market is primed for growth, driven by technological advancements and healthcare demand. Addressing challenges requires strategic investments in research, cross-disciplinary collaborations, and robust regulatory frameworks to navigate ethical and technical landscapes while capitalizing on emerging opportunities for market innovation and expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Biomarkers Market

The Brain Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Improved knowledge of neurologic diseases and R&D investment to treat growing geriatric population with brain disorder
    • Need for invasive brain tastings, effective drug development, faster diagnosis, and new treatment option
    • Detection and interpretation to support clinical decisions and patient interventions
  • Market Restraints
    • Lack of consumer awareness
  • Market Opportunities
    • Evolving biomarker data management platforms to support biomarker-guided drug development and translational research
    • Incorporation of detectable parameters with brain biomarkers to improve clinical decision making
  • Market Challenges
    • Complexity of neuroinflammation exacerbated by substantial biological heterogeneity

Porter's Five Forces: A Strategic Tool for Navigating the Brain Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Biomarkers Market

A detailed market share analysis in the Brain Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Biomarkers Market

A strategic analysis of the Brain Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Advanced Brain Monitoring, Inc, Biognosys AG, BrainScope Company, Inc., F. Hoffmann-La Roche AG, GE Healthcare, Johnson & Johnson, Lifesign LLC, Magstim EGI, Merck KGaA,, Natus Medical Inc., NeuroVista Corporation, Nexus-DX, PhenoSwitch Bioscience, Seimens Healthnineers, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Biomarker Analyzers and Biomarker Test Kits.
  • Based on Indication, market is studied across Alzheimer's Disease, Huntington's Disease, MND & ALS, Parkinson's Disease, and Stroke.
  • Based on End-Users, market is studied across Ambulatory Surgical Centers, Diagnostic Laboratories, Hospitals, and Research Laboratories.
  • Based on Application, market is studied across Diagnosis and Drug Discovery & Development.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Improved knowledge of neurologic diseases and R&D investment to treat growing geriatric population with brain disorder
      • 5.1.1.2. Need for invasive brain tastings, effective drug development, faster diagnosis, and new treatment option
      • 5.1.1.3. Detection and interpretation to support clinical decisions and patient interventions
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of consumer awareness
    • 5.1.3. Opportunities
      • 5.1.3.1. Evolving biomarker data management platforms to support biomarker-guided drug development and translational research
      • 5.1.3.2. Incorporation of detectable parameters with brain biomarkers to improve clinical decision making
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of neuroinflammation exacerbated by substantial biological heterogeneity
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Brain Biomarkers Market, by Product

  • 6.1. Introduction
  • 6.2. Biomarker Analyzers
  • 6.3. Biomarker Test Kits

7. Brain Biomarkers Market, by Indication

  • 7.1. Introduction
  • 7.2. Alzheimer's Disease
  • 7.3. Huntington's Disease
  • 7.4. MND & ALS
  • 7.5. Parkinson's Disease
  • 7.6. Stroke

8. Brain Biomarkers Market, by End-Users

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Diagnostic Laboratories
  • 8.4. Hospitals
  • 8.5. Research Laboratories

9. Brain Biomarkers Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnosis
  • 9.3. Drug Discovery & Development

10. Americas Brain Biomarkers Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Brain Biomarkers Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Brain Biomarkers Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Advanced Brain Monitoring, Inc
  • 2. Biognosys AG
  • 3. BrainScope Company, Inc.
  • 4. F. Hoffmann-La Roche AG
  • 5. GE Healthcare
  • 6. Johnson & Johnson
  • 7. Lifesign LLC
  • 8. Magstim EGI
  • 9. Merck KGaA,
  • 10. Natus Medical Inc.
  • 11. NeuroVista Corporation
  • 12. Nexus-DX
  • 13. PhenoSwitch Bioscience
  • 14. Seimens Healthnineers
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. BRAIN BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. BRAIN BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BRAIN BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BRAIN BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRAIN BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRAIN BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TEST KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MND & ALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. BRAIN BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. BRAIN BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023